Scribe Therapeutics, Inc. (SCTX)

Nasdaq · Biological Products, (No Diagnostic Substances) · Inc. DE

What they're doing

Between 2026-06-21 and 2026-09-19, public records show 7 signals for Scribe Therapeutics, Inc.. Most notable: 2026-07-24: Aghazadeh Behzad; Avoro Capital Advisors LLC; Avoro Ventures LLC (director) bought $35.0M of stock; 2026-07-27: 4 insiders bought $71.1M within 14 days; 2026-07-27: GORDON CARL L (director) bought $15.0M of stock. Federal contract obligations over the last 24 months total $0. This summary was assembled automatically from SEC EDGAR, USAspending.gov, U.S. Senate lobbying disclosures and Wikimedia pageview counts.

Generated 2026-09-19 from public records.

Signals, last 12 months

  1. Insider purchase
    Aghazadeh Behzad; Avoro Capital Advisors LLC; Avoro Ventures LLC (director) bought $144k of stock
  2. Insider buying cluster
    4 insiders bought $71.1M within 14 days
  3. Insider purchase
    GORDON CARL L (director) bought $15.0M of stock
  4. Insider purchase
    ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC (director) bought $15.0M of stock
  5. Insider purchase
    AH Bio Fund II, L.P.; AH Equity Partners Bio II, L.L.C.; AH Bio Fund III, L.P.; AH Equity Partners Bio III, L.L.C.; Andreessen Marc L; HOROWITZ BENJAMIN A (ten_percent_owner) bought $5.0M of stock
  6. Insider purchase
    Aghazadeh Behzad; Avoro Capital Advisors LLC; Avoro Ventures LLC (director) bought $35.0M of stock
  7. Insider purchase
    Aghazadeh Behzad; Avoro Capital Advisors LLC; Avoro Ventures LLC (director) bought $1.1M of stock

Insider transactions

DateInsiderRoleCodeSharesPriceValue
2026-07-28Aghazadeh Behzad; Avoro Capital Advisors LLC; Avoro Ventures LLCdirectorP7,90518.25$144,266
2026-07-27AH Bio Fund II, L.P.; AH Equity Partners Bio II, L.L.C.; AH Bio Fund III, L.P.; AH Equity Partners Bio III, L.L.C.; Andreessen Marc L; HOROWITZ BENJAMIN Aten percent ownerC2,051,742
2026-07-27AH Bio Fund II, L.P.; AH Equity Partners Bio II, L.L.C.; AH Bio Fund III, L.P.; AH Equity Partners Bio III, L.L.C.; Andreessen Marc L; HOROWITZ BENJAMIN Aten percent ownerC697,650
2026-07-27AH Bio Fund II, L.P.; AH Equity Partners Bio II, L.L.C.; AH Bio Fund III, L.P.; AH Equity Partners Bio III, L.L.C.; Andreessen Marc L; HOROWITZ BENJAMIN Aten percent ownerP333,33315$4,999,995
2026-07-27GORDON CARL LdirectorC348,825
2026-07-27GORDON CARL LdirectorP1,000,00015$15,000,000
2026-07-27ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLCdirectorC348,825
2026-07-27ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLCdirectorP1,000,00015$15,000,000
2026-07-27Doudna Jennifer Aten percent ownerC12,511
2026-07-24Aghazadeh Behzad; Avoro Capital Advisors LLC; Avoro Ventures LLCdirectorP2,333,33315$34,999,995
2026-07-24Aghazadeh Behzad; Avoro Capital Advisors LLC; Avoro Ventures LLCdirectorP50,00022.31$1,115,500
2026-07-23Lucas SvetlanaofficerP3,00015$45,000
2026-07-23Parrot DavidofficerP1,33315$19,995
2026-07-23Parrot DavidofficerP1,33315$19,995

Federal contracts

No federal contract actions on record for this recipient mapping.

Lobbying

No federal lobbying filings on record for this client mapping.

Public attention

No Wikipedia pageview data linked to this company.

Recent filings

Scribe Therapeutics, Inc. (SCTX): insider trades, federal contracts, lobbying | IP Files